coagulation conference mexico city 2013
TRANSCRIPT
![Page 1: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/1.jpg)
Lessons from Genome-Wide Association Studies in Venous Thrombosis
NOTE: VIEW ON FULL SCREEN
Raul A. DeLa Cadena, M.D. Temple University School of Medicine
Philadelphia, Pennsylvania “La Mujer” David Alfaro Siqueiros 1964-1971
![Page 2: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/2.jpg)
GWAS
![Page 3: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/3.jpg)
GWAS and Venous Thrombosis
• The revolution started with: – Human Genome – HapMap projects
Lander ES, et al.: Nature, 2001 Venter JC, et al.: Science, 2001
![Page 4: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/4.jpg)
Risk Factors known prior to GWAS Era
![Page 5: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/5.jpg)
• Until the end of the 20th Century: Association and linkage studies.
• Compared to the number of studies performed, successes in VT were relatively modest despite notable discoveries.
• SERPINC1, PROC, and PROS1.. – Association with VT over 25 years.
• F5, F2, ABO y FGG – More frequent SNPs and associated with VT.
Risk Factors Known prior to GWAS Era
![Page 6: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/6.jpg)
F5 Gene
• Rs6025 • Factor V Leyden • R506Q • Resistence activated Proteina C • Allele Q506 has a frequency of 5% in
Caucassians with an increased risk of about 3 times compared to heterozygous carriers
Bertina RM, et al.: Nature 1994 Seligson U, et al.: N Engl J Med 2001
![Page 7: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/7.jpg)
F2 Gene
• Rs1799963-A • 20210 • G20210A • Elevated plasma levels of FII • Allele G20210A associated with an increased
risk of about 2.5 times when compared with heterozygous carriers
Poort SR, et al.: Blood 1996 Seligson U, et al.: N Engl J Med 2001
![Page 8: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/8.jpg)
Gene FGG
• Rs2066865.
• Frequency of approximately 25%.
• Modulating the levels of a form of fibrinogen in plasma by affecting a polyadenation site.
Tregouet DA, et al.: Blood, 2009
![Page 9: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/9.jpg)
ABO Blood Groups
• A1 • B • Associated with VT apparently by increased
levels of plasma FVIII y vWF due to decrease clearance but not clearly determined today.
• Associated frequency of about 30%
Wu O, et al.: J Thromb Haemost 2008
![Page 10: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/10.jpg)
Contributions due to the GWAS Era
![Page 11: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/11.jpg)
New Risk Factors from the GWAS Era
• First study conducted by Bezemer et al. – 200,000 SNPs. – DNA analysis performed in group and individually. – Two novel susceptibility loci identified: GPVI y F11
• Second study concentrated in approximately 300,000 SNPs. – No new susceptibility loci for VT identified, but strong
associations were observed at two known loci, the FV and the ABO genes.
Bezemer ID, et al.: JAMA 2008
Tregouet DA, et al.: Blood, 2009
![Page 12: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/12.jpg)
GP6 • Allele rs1613662-G • Confirmed by three other studies. • Substitution A/G, amino acid 219, exon 4,
gene coding for GP6: isoforms GPVIa y GPVIb. • GPVI for collagen in platelets
Bezemer ID, et al.: JAMA 2008 Snoep JD, et al.: J Thromb Haemost, 2010
![Page 13: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/13.jpg)
F11
• Alleles rs2289252 y rs2036914 • Additive effect regulating the plasma levels of
FXI.
Bezemer ID, et al.: JAMA 2008 Meijers JC, et al.: N Engl J Med, 2000
![Page 14: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/14.jpg)
New Susceptibility Locus on Chromosome 6p24.1
• Allele rs169713 • Allele lies about 100kb downstream of the
HIVEP1 gene. It belongs to a family of genes participating in transcriptional regulation of a variety of inflammatory genes.
Morange PE, et al.: Am J Hum Genet, 2010
![Page 15: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/15.jpg)
GWAS contribution in the understanding of shorthened aPTT
• Short aPTT, a laboratory tool, due to is association with VT.
• A study with 1477 normal subjects with the identification of 3 SNPs – Rs27431672 (F12) – Rs9898 (HRG) – Rs710446 (KNG1)
Tripodi A, et al.: Blood, 2004 Houlihan LM, et al.: Am J Hum Genet, 2010
![Page 16: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/16.jpg)
F12, HRG, KNG1 Association con Thrombosis
• Study with 1,542 patients with VT and 1,110
normal controls. • The rs710446 (KNG1) was found associated
with a risk for thrombosis. • Confirmed with another study with 596
patients and 590 normal controls. • Rs710446 (KNG1), consists of a single amino
acid substitution (Ile581Thr) in KNG1 (HK).
Morange PE, et al.: Blood, 2011
![Page 17: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/17.jpg)
HK
Domain 3
Domain 2
Domain 1
Domain 4 Domain 5
Domain 6
This image cannot currently be displayed. PK TTPa
![Page 18: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/18.jpg)
Additional Information Associated with VT as a result of GWAS
![Page 19: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/19.jpg)
Additional Information from GWAS
• Some GWAS) studies were conducted within the context of the pathophysiology of VT and instead of VT risk assessment.
• One of them evaluated SNPs to study the variation of Protein C in plasma.
• Conducted with 8,000 participants identified 5 genes. – PROCR which codes for the Proteina C receptor identified rs867186 explaining
about 10% of Protein C variability in plasma. It is associated with an increased susceptibility of the receptor to proteolysis and thus associated with an increased risk to VT.
• Additional genes were identified, namely EDEM2, BAZIB, y GCKR requiring careful attention for their association with VT. – GCKR gene plays a major role in the levels of reactive C protein, in favor of the
known association between inflammation and coagulation.
Dehghan A, et al.: Circulation, 2011
![Page 20: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/20.jpg)
INTRINSIC PATWAY
EXTRINSIC PATHWAY
FXII
FXI
FIX
Contact System Kallikrein-Kinin System
FV FII
FVIII FVIIIa Trombin
TFPI
AT-III
Protein C rs6025 F5 rs1799963F2
SERPINC1
rs2289252 y rs2036914 F11
Rs710446 KNG1
aPTT
![Page 21: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/21.jpg)
Trombin Fibrinogen
vWF
Fibrin Generation
FXIII
α2-anti-plasmin
rs1799963 FGG
rs2154299 rs12194855
F13A1
ABO B, A1
![Page 22: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/22.jpg)
Platelets
Platelet Microparticules
GPIb
GPIIb/IIIa
VIIIa
FIXa Ca
FX
FVa FXa
Ca
FIIa
FII
Fibrinogen
PF4
TSP1
FXIIIa
rs2154299 rs12194855
F13A1
rs1799963 FGG
ABO B, A1
![Page 23: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/23.jpg)
Normal Endothelium
NO PGI2 ADPase
Heparan + ATIII
Inhibition FXa + Trombin
tPA uPA
Plasmin Plasminogen
Trombomodulin
Protein C Protein Ca Protein S
Trombin
FVa FVIIIa
Platelet Inhibition
PAI
PROC
PROS1
![Page 24: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/24.jpg)
What to do now?
GWAS
![Page 25: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/25.jpg)
Case Report
Saygi S., et al.: Echocardiography 2011;28:E64-E67
![Page 26: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/26.jpg)
A 46-year old man admitted to ER with: 1. Chest pain 2. Diaphoresis
History, mild smoker. 1. Anxious 2. Hypotensive (70/50 mm Hg
3. EKG:
• Bradycardia • Prolongation QRS complex • Total AV block • ST elevation
Troponin I 15.1 ng/ml (reference range <0.01 ng/ml) Diagnosis of acute myocardial infarction complicated with cardiogenic shock and total AV block was made.
Case Report
![Page 27: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/27.jpg)
Coronary Angiogram
Normal right and circumflex coronary artery and a noncritical plaque in Left anterior descending artery. During coronary angiography chest pain was resolved abruptly and Electrocardiographic changes dissapeared. Patient transferred to ICU. After administration of heparin and aspirin Transthoracic echocardiography was performed. • Suspicion of a mass placed in noncoronary sinus of Valsalva Transesophageal echocardiography was performed.
![Page 28: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/28.jpg)
Coronary Angiogram - Normal
![Page 29: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/29.jpg)
•A round mass (25 x 10mm) filling the noncoronary sinus of Valsalva.
•The mass was highly mobile and prolapsing into right coronary artery ostium intermittently.
Transesophageal Echocardiography
![Page 30: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/30.jpg)
Platelet count - Normal AT-III - Normal Protein S - Normal Protein C - Normal Factor V Leiden - Normal Prothrombin - Normal Factor XII - Normal Methyltetrahydrofolate (MTHFR) - Normal
SPECIALIZED COAGULATION LABORATORY
![Page 31: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/31.jpg)
Surgical Procedure
Emergency surgery, a solid round mass 25mm diameter occupying the Noncoronary sinus of Valsalva was seen and removed. Mass penetrated into the right coronary artery ostium.
![Page 32: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/32.jpg)
Normal Endothelium
NO PGI2 ADPase
Heparan + ATIII
Inhibition FXa + Trombina
tPA uPA
Plasmin Plasminogen
Trombomodulina
Proteina C Proteina Ca Proteina S
Trombina
FVa FVIIIa
Inibicion Plaquetas
PAI
PROC
PROS1
Homozygote Rs1799768
PAI-1 G4/G5
![Page 33: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/33.jpg)
What to do now?
Homozygote Rs1799768
PAI-1 G4/G5
![Page 34: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/34.jpg)
Conclusions
• GWAS, require a large number of participants, for instance, to identify 10 SNPs associated with cardiovascular disease, over 140,000 subjects needed to be included.
• Noteworthy to mention is that a gene housing a rare mutation associated with VT may house SNPs with a moderate risk of thrombosis.
• For instance by the use of the deep gene analysis method like the one use for F9 a rare mutation was found (R338L) associated with elevated numbers of FIXa and thrombotic events in young adults which is expressed in other family members and known as FIX Padua.
Schunkert H, et al.: Nat Genet 2011 Simioni P, et al.: N Engl J Med, 2009
![Page 35: COAGULATION CONFERENCE MEXICO CITY 2013](https://reader031.vdocument.in/reader031/viewer/2022022413/58ed98cf1a28abfb728b4693/html5/thumbnails/35.jpg)
Lessons from Genome-Wide Association Studies in Venous Thrombosis
THANK YOU FOR YOUR ATTENTION
Raul A. DeLa Cadena, M.D. Temple University School of Medicine
Philadelphia, Pennsylvania “La Mujer” David Alfaro Siqueiros 1964-1971